Array Biopharma (ARRY) Adds to Gains; Shares Up 70%
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Array Biopharma (NASDAQ: ARRY) is pushing to the highs of the session. Shares are now up 70% after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic melanoma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Aetna (AET) Adds Sarepta's (NASDAQ: SRPT) Exondys 51 to Coverage List; Will be Effective Nov. 1st
- Option volume flows
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!